Lecozotan

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Lecozotan is an investigational drug developed by Wyeth aimed at improving cognitive function in people with Alzheimer's disease. It is a selective, competitive antagonist of the brain’s 5-HT1A receptor. By blocking this receptor, Lecozotan increases the potassium-stimulated release of acetylcholine and glutamate, chemicals involved in memory and learning. The drug was studied in clinical trials, and the first Phase III trial was completed by June 2008. There is no evidence it was ever approved for medical use, so it remains experimental.